Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes and Weight-Loss drug help people quit meth?

NCT ID NCT07825857

Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 21, 2026 · Updated 2 times

Summary

Researchers at UT Southwestern Medical Center are testing whether tirzepatide, a drug approved for diabetes and weight loss, can help people with moderate to severe methamphetamine use disorder reduce or stop using the drug. The trial enrolls 228 adults aged 18 to 65 who are overweight or obese and want to cut down on meth. Participants receive weekly injections of either tirzepatide or a saline placebo for 26 weeks, and researchers track urine drug screens, craving scores, and whether people stay in treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide, a once-weekly injectable drug also known as Zepbound or Mounjaro
What this could lead to
If it works, this could point toward the first medication option for methamphetamine use disorder, a condition with no approved drug treatments.
What could go wrong
This is a phase 2 trial, so even positive results would need larger studies before becoming a standard treatment. Tirzepatide can cause nausea, vomiting, and other digestive side effects, and some participants may stop treatment early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 228 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * be aged 18 to 65 years; * have moderate or severe methamphetamine use disorder; * have active pattern of methamphetamine use; * be interested in reducing or stopping methamphetamine use; * be able and willing to provide informed consent, comply with all study procedures, and adhere to weekly study medication injections; * be overweight or obese (body mass index ≥25 kg/m²); and * (only for biological females) agree to use acceptable contraception and undergo urine pregnancy testing unless unable to become pregnant Exclusion Criteria: * report using any glucagon like peptide 1 receptor agonists (GLP-1RA, including tirzepatide), sulfonylureas, or insulin in the past 90 days; * have a current eating disorder or severe alcohol or substance use disorder; * have personal or family history of medullary thyroid carcinoma, history of multiple endocrine neoplasia type 2, or hypersensitivity, angioedema, or anaphylaxis to GLP-1RAs or tirzepatide; * have Stage 3 or higher chronic kidney disease, inadequately controlled diabetes, history of diabetic retinopathy, any unstable or serious medical or psychiatric condition, or any other reason or clinical condition that may either interfere with study participation or make the study participation unsafe (per investigator judgement); * are currently pregnant, breastfeeding, or planning pregnancy; * have received an investigational drug within 30 days of informed consent; * require psychiatric hospitalization; * have recent suicidal or current homicidal ideation; * are incarcerated or in court-mandated residential placement; * have unsafe use of alcohol, benzodiazepines, sedative/hypnotics, or other substances; or * have use of concurrent medications that may pose safety risks or interfere with study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Methamphetamine use disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

methamphetamine dependence substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Methamphetamine use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center of Substance Use and Health

    San Francisco, California, 94102, United States

  • Oklahoma State University (OSU) Center for Health Services

    Tulsa, Oklahoma, 74136, United States

  • University of Southern California (USC)

    Los Angeles, California, 90032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.